Stockscreener 앱 받기
32.29
1.19%
0.38
시간 외 거래:
32.29
Vaxcyte Inc 주식(PCVX)의 최신 뉴스
Reversal Confirmed Vaxcyte Inc. Stock Rallies Above MATrade Risk Report & Risk Adjusted Buy/Sell Alerts - newsyoung.net
Are Bears Losing Grip on Vaxcyte Inc.Market Risk Summary & High Accuracy Swing Trade Signals - kangso.co.kr
Vaxcyte Inc. Ranks High in Smart Money TrackerWeekly Trend Report & Verified Trade Idea Suggestions - newsyoung.net
Is Vaxcyte Inc. in Accumulation Phase Now2025 Market Overview & Real-Time Volume Surge Alerts - kangso.co.kr
Mizuho Securities Reiterates Buy Rating for Vaxcyte with $163 Price Target - AInvest
Can Vaxcyte Inc. deliver alphaPortfolio Gains Summary & High Accuracy Trade Alerts - metrotimes.co.kr
Vaxcyte Inc. Flashes Rebound Signal in Oversold ConditionQuarterly Profit Report & Weekly Breakout Opportunity Watchlist - metal.it
Vaxcyte Inc. Shows Support at Fibonacci LevelQuarterly Earnings Report & Low Risk Investment Opportunities - beatles.ru
Vaxcyte Q2 Earnings: Progress in Vaccine Development and $2.8 Billion Cash Position - AInvest
Why Vaxcyte’s Stock is on the Rise - TipRanks
Vaxcyte Inc. Rebounds From Oversold Zone — Now WhatTriple Digit Growth Focused Trade Plan Reviewed - 선데이타임즈
Vaxcyte Reports Progress in Vaccine Development - TipRanks
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Cuts Target Price to $116 - 富途牛牛
Guggenheim lowers Vaxcyte stock price target to $116 on trial timeline shifts - Investing.com Canada
Vaxcyte’s Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
Pipeline Insight into Pneumococcal Disease Treatments: Sanofi, Alopexx, and Virometix Lead the Way - AInvest
Vaxcyte, Inc. shares fall 9.56% intraday after FDA interactions and Phase 3 clinical program finalization. - AInvest
Vaxcyte price target lowered to $50 from $85 at TD Cowen - TipRanks
Vaxcyte’s Strategic Adjustments and Optimized Trials Drive Buy Rating - TipRanks
Vaxcyte Q2 Loss Widens 11%, Ends Quarter with $2.83B in Cash - AInvest
Vaxcyte Q2 EPS $1.22, beats consensus $1.16; CEO discusses Phase 3 program for VAX-31. - AInvest
Vaxcyte (PCVX) Q2 Loss Widens 11% - AOL.com
Vaxcyte (PCVX) Q2 Loss Widens 11% - The Motley Fool
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Cuts Target Price to $50 - 富途牛牛
Promising Prospects for Vaxcyte’s VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating - TipRanks
Vaxcyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) - GlobeNewswire
MACD Signals Flash Warning for Vaxcyte Inc. StockMulti-Bagger Potential Stock Forecast Tools Released - metal.it
What is the dividend policy of Vaxcyte Inc. stockStay ahead with advanced stock screening tools - Jammu Links News
How strong is Vaxcyte Inc. company’s balance sheetUnprecedented profits - Jammu Links News
How does Vaxcyte Inc. compare to its industry peersDiscover stocks with explosive upside potential - Jammu Links News
Is Vaxcyte Inc. stock overvalued or undervaluedAchieve breakthrough performance in the market - Jammu Links News
Is Vaxcyte Inc. a growth stock or a value stockFree Investment Risk Control - Jammu Links News
How does Vaxcyte Inc. generate profit in a changing economyAchieve rapid financial growth with smart picks - Jammu Links News
When is Vaxcyte Inc. stock expected to show significant growthUnlock powerful stock screening tools today - Jammu Links News
Is it the right time to buy Vaxcyte Inc. stockDiscover stocks with explosive growth potential - Jammu Links News
What drives Vaxcyte Inc. stock priceInvest smarter with real-time trading signals - Jammu Links News
What are the latest earnings results for Vaxcyte Inc.Stay ahead with advanced stock screening tools - Jammu Links News
What are analysts’ price targets for Vaxcyte Inc. in the next 12 monthsBuild a diversified portfolio for steady growth - Jammu Links News
Should I hold or sell Vaxcyte Inc. stock in 2025Phenomenal capital appreciation - Jammu Links News
What institutional investors are buying Vaxcyte Inc. stockPowerful profit generation - Jammu Links News
Vaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in Infants - MSN
InvestingPro’s Fair Value model predicted Vaxcyte’s 46% decline By Investing.com - Investing.com
What markets is Vaxcyte Inc. expanding into Is FDUS stock a good long term investment optionFree Stock Target Finder That Work - Jammu Links News
We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth - 富途牛牛
11 Best Future Stocks to Buy Now - Insider Monkey
What makes Vaxcyte Inc. stock price move sharplyMarket Entry and Exit Point Tips From Traders - metal.it
0.94%
1.72%
자본화:
|
볼륨(24시간):